MD ANDERSON THERAPEUTICS DISCOVERY DIVISION
Within The University of Texas MD Anderson Cancer Center lies a powerful engine driving the future of new targeted, immune- and cell-based therapies: the Therapeutics Discovery Division. Therapeutics Discovery eliminates the bottlenecks that hamper traditional drug discovery, with a multidisciplinary team of dedicated researchers, doctors, drug developers and scientific experts working together to develop small-molecule drugs, biologics and cellular therapies. Our unique structure and collaborative approach allow the team to work with agility, bringing novel medicines from concept to clinic quickly and efficiently – all under the same roof.
The Therapeutics Discovery Division is built around four platforms: The Institute for Applied Cancer Science (IACS), ORBIT (Oncology Research for Biologics and Immunotherapy Translation), TRACTION (Translational Research to Advance Therapeutics and Innovation in Oncology) and the Neurodegeneration Consortium.
The IACS platform is focused on discovering and developing the next generation of small-molecule targeted therapies, driven by the needs we see in our patients. The team aligns world-class drug discovery and development research with the science and clinical care for which MD Anderson is known. We work in a fast-paced, milestone-driven environment with a focus on team science and interdisciplinary research. Our unique approach has created a biotech-like engine within the walls of the nation’s leading cancer center to bring life-saving medicines to our patients more quickly and effectively. This model already has achieved results, with multiple programs currently in clinical and late-stage preclinical development.
The Institute Associate Scientist II in the structural chemistry group of the Institute for Applied Cancer Science (IACS) participates in cross-functional research to advance our drug discovery projects from early exploratory efforts through lead optimization, ultimately delivering therapeutic agents of benefit to patients. As part of the IACS team, the Institute Associate Scientist II will deliver high-quality protein samples for a variety of crucial applications, including in vitro assays, X-ray crystallography, and cryo-electron microscopy.
By joining the Therapeutics Discovery Division, you have the opportunity to use your talents to make a direct impact on the lives of our patients. We are seeking a highly motivated and collaborative individual to become a part of our team. The ideal candidate will have experience expressing and purifying recombinant proteins in one or more expression systems.
Bachelor’s degree in Biochemistry, Chemistry or related field.
Preferred: Master’s degree in Biochemistry, Chemistry or related field.
At least one year experience expressing recombinant proteins from E. coli, insect cell, or mammalian cell systems. Experience with FPLC-based protein purification instruments. Excellent communication, writing and organizational skills.